We use cookies to help provide you with the best possible online experience.
By using this site, you agree that we may store and access cookies on your device. Cookie policy.
Cookie settings.
Functional Cookies
Functional Cookies are enabled by default at all times so that we can save your preferences for cookie settings and ensure site works and delivers best experience.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Access to tirzepatide (Mounjaro) through primary care
For managing overweight and obesity
As you will be aware, NHS England is making tirzepatide (Mounjaro) available in a phased approached over the next few years. NICE guidelines say that in order to gain access to tirzepatide (Mounjaro) on the NHS, patients must also be referred on to a diet and exercise support programme.
Although it has been announced that it will become available in primary care settings from Monday, 23 June (for a specific patient cohort) arrangements are being made to mobilise a provider of the necessary Behavioural Support for Obesity Prescribing (BSOP) that is specified in the NICE guidelines.
Until this service is in place in Kent and Medway, it is not possible to prescribe tirzepatide (Mounjaro) in primary care.
Please also note there is no provider of tirzepatide (Mounjaro) available under right to choose.
We are aware that this situation may be difficult for practices to explain to patients. If you are approached, NHS England has produced answers to some frequently asked questions for patients.
We will provide further information when it is available.
Published: Jun 23, 2025